Targeting tumor angiogenesis: Comparison of peptide and polymer-peptide conjugates

Journal of Nuclear Medicine

Volumn 46, Issue 9, 2005, Pages 1552-1560

  Line, Bruce R ^a,b   Mitra, Amitava ^b   Nan, Anjan ^b   Ghandehari, Hamidreza ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Angiogenesis; Biodistribution; HPMA copolymers; RGD peptides; Targeted delivery

Indexed keywords

COPOLYMER; LYSYLALANYLCYSTEINYLASPARTYLCYSTEINYLARGINYLGLYCYLASPARTYLCYSTEINYLPHENYLALANYLCYSTEINYLGLYCINE; LYSYLALANYLCYSTEINYLASPARTYLCYSTEINYLARGINYLGLYCYLGLUTAMYLCYSTEINYLPHENYLALANYLCYSTEINYLGLYCINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; ARGINYL GLYCYL GLUTAMIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYL-GLYCYL-GLUTAMIC ACID; ARGINYLGLYCYLASPARTIC ACID; HYDROXYPROPYL METHACRYLATE; METHACRYLIC ACID DERIVATIVE; OLIGOPEPTIDE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL ADHESION; CONJUGATION; CONTROLLED STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MOTIF; RADIOACTIVITY; TUMOR LOCALIZATION; ANIMAL; ANTIBODY SPECIFICITY; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; HUMAN; MALE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PROSTATE TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRIN ALPHAVBETA3; MALE; METABOLIC CLEARANCE RATE; METHACRYLATES; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

EID: 27744584734     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
3. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
4. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptor for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15:542-546.
5. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
6. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted proapoptotic peptides. Nat Med. 1999;5:1032-1038.
7. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release. 2005;102:191-201.
8. Mitra A, Nan A, Ghandehari H, McNeill E, Mulholland J, Line BR. Technetium-99m labeled N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers: synthesis, characterization and in vivo bio distribution. Pharm Res. 2004;21:1153-1159.
9. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-284.
10. Strohalm J, Kopecek J. Poly N-(2-hydroxypropyl)methacrylamide. 4. Heterogeneous polymerization. Angew Makromol Chem. 1978;70:109-118.
11. Rejmanova P, Labsky J, Kopecek J. Aminolyses of monomeric and polymeric p-nitrophenyl esters of methacryloylated amino acids. Makromol Chem. 1977;178:2159-2168.
12. Lee JH, Kopeckova P, Kopecek J, Andrade JD. Surface properties of copolymers of alkyl methacrylates with methoxy (polyethylene oxide) methacrylates and their application as protein-resistant coatings. Biomaterials. 1990;11:455-464.
13. Winnard P Jr, Chang F, Rusckowski M, Mardirossian G, Hnatowich DJ. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl Med Biol. 1997;24:425-432.
14. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med. 1998;4:408-414.
15. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol. 1998;184:119-122.
16. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
17. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J. 2000;6(suppl 3):S245-S249.
18. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2:83-90.
19. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y). 1995;13:265-270.
20. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis. 2003;20:203-213.
21. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol. 2002;29:3-9.
22. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
23. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA. 1996;93:14765-14770.
24. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 1993;66:181-196.
25. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100.
26. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002;2:266-276.
27. Blumenthal RD, Kashi R, Sharkey RM, Goldenberg DM. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. Int J Cancer. 1995;61:557-566.
28. Mehvar R, Reynolds JM, Shepard TL. Disposition of fluorescein-labelled dextran (150 kD) in isolated perfused livers from control and diabetic rats. Life Sci. 1991;49:1699-1706.
29. Mehvar R, Reynolds JM. Pharmacokinetics of 70-kilodalton fluorescein-dextran in experimental diabetes mellitus. J Pharmacol Exp Ther. 1993;264:662-669.
30. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 2002;17:641-646.
31. Poethko T, Schottelius M, Thumshirn G, et al. Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892-902.
32. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60:2497-2503.
33. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 2002;62:6146-6151.
34. Kissel M, Peschke P, Subr V, et al. Biodistribution of charged poly[N-(2-hydroxypropyl) methacrylamide] in tumor bearing rats. [Abstract]. Proceedings of the 28th International Symposium on Controlled Release of Bioactive Materials; June 23-27, 2001; San Diego, CA: 1346-1347.
35. Kissel M, Peschke P, Subr V, et al. Synthetic macromolecular drug carriers: bio distribution of poly[(N-2-hydroxypropyl)methacrylamide] copolymers and their accumulation in solid rat tumors. PDA J Pharm Sci Technol. 2001;55:191-201.
36. Seymour LW, Miyamoto Y, Maeda H, et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer. 1995;31A:766-770.
37. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061-1071.
38. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69.
39. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
40. 18F]galacto-RGD. Plos Med. 2005;2:244-252.
41. Ruoslahti E, Giancotti FG. Integrins and tumor cell dissemination. Cancer Cells. 1989;1:119-126.